Cargando…
Progress toward active or passive HIV-1 vaccination
AIDS is a preventable disease. Nevertheless, according to UNAIDS, 2.1 million individuals were infected with HIV-1 in 2015 worldwide. An effective vaccine is highly desirable. Most vaccines in clinical use today prevent infection because they elicit antibodies that block pathogen entry. Consistent w...
Autores principales: | Escolano, Amelia, Dosenovic, Pia, Nussenzweig, Michel C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Rockefeller University Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5206506/ https://www.ncbi.nlm.nih.gov/pubmed/28003309 http://dx.doi.org/10.1084/jem.20161765 |
Ejemplares similares
-
Sequencing, cloning, and antigen binding analysis of monoclonal antibodies isolated from single mouse B cells
por: Viant, Charlotte, et al.
Publicado: (2021) -
HIV-specific humoral immune responses by CRISPR/Cas9-edited B cells
por: Hartweger, Harald, et al.
Publicado: (2019) -
Antibody elicited by HIV-1 immunogen vaccination in macaques displaces Env fusion peptide and destroys a neutralizing epitope
por: Abernathy, Morgan E., et al.
Publicado: (2021) -
HIV Vaccine Design to Target Germline Precursors of Glycan-Dependent Broadly Neutralizing Antibodies
por: Steichen, Jon M., et al.
Publicado: (2016) -
Specifically modified Env immunogens activate B-cell precursors of broadly neutralizing HIV-1 antibodies in transgenic mice
por: McGuire, Andrew T., et al.
Publicado: (2016)